Stage at presentation and survival of white and black patients with prostate carcinoma

Brawn, Peter N.; Johnson, Ernest H.; Kuhl, Daniel; Riggs, Mark; Speights, V. O.; Johnson, Charles F.; Pandya, Perry; Lind, Mary L.; Bell, Norma F.

doi:10.1002/1097-0142(19930415)71:8<2569::aid-cncr2820710822>3.0.co;2-r

Cited by 132 publications

(42 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some patients have a genetic predisposition to prostate cancer 1,2 while racial and socioeconomic factors influence detection and prognosis in others. 3,4 Each year in the United States, prostate cancer is diagnosed in over 180,000 men and is responsible for over 30,000 deaths. 5 The absence of specific detection and prognostic markers compels physicians to rely on non-specific screening tests and nomograms to facilitate early detection and prognosis.…”

supporting

confidence: 91%

Sharpening the Tools for Prostate Cancer Detection in the PSA Era: What's the Point?

Leach¹

2003

Cancer Biology & Therapy

View full text Add to dashboard Cite

supporting

confidence: 91%

Sharpening the Tools for Prostate Cancer Detection in the PSA Era: What's the Point?

Leach¹

2003

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…This finding is consistent with other studies reporting similar survival rates for black and white men with prostate cancer, once adjusted for stage, grade and age [29][30][31] or socio-economic factors [32], or access to medical care [33]. Despite the survival advantage with the use of ADT, the racial differences in use did not translate into survival differences, suggesting that physicians might be appropriately selecting patients for delayed or no therapy.…”

Section: Discussionmentioning

confidence: 99%

Use of androgen deprivation therapy for metastatic prostate cancer in older men

et al. 2008

View full text Add to dashboard Cite

OBJECTIVETo assess factors associated with early or delayed androgen deprivation therapy (ADT) among men diagnosed with metastatic prostate cancer, and to assess the relationship between ADT and overall survival, as there is uncertainty about the ideal timing for initiating ADT in men with metastatic prostate cancer.PATIENTS AND METHODSWe studied a population‐based cohort of American men aged ≥66 years diagnosed with metastatic prostate cancer during 1992–2002 and followed to 2003. We assessed the receipt of ADT early (≤4 months from diagnosis), delayed (>4 months), or not at all, using multinomial logistic regression to identify factors associated with treatment, and Cox proportional‐hazard models to assess whether treatment was associated with survival.RESULTSOverall, 69.5% of men received early ADT and 7.3% delayed. Adjusted rates of early ADT were lower for black than white men (58.3% vs 71.0%), and of delayed ADT were higher for black than white men (12.7% vs 6.2%). Receipt of ADT was associated with improved survival (adjusted hazard ratio 0.69, 95% confidence interval 0.66–0.73). The benefit of early treatment did not differ from delayed treatment (P = 0.58).CONCLUSIONSA large minority of men with metastatic prostate cancer, particularly black men, receive delayed or no ADT. Early or delayed ADT was associated with similarly prolonged survival. After controlling for patient and tumour characteristics, survival did not differ by race, and receipt of ADT did not contribute to racial differences in survival.

show abstract

“…5 The mortality rate in black men is twice that of white men (40 and 20/ 100 000, respectively). 6 The highest reported mortality from this disease occurs in people of African descent from the Caribbean islands of St Vincent and Bermuda. 7 It has therefore been stated that prostate cancer, in men of African descent is different from that of other races.…”

Section: Introductionmentioning

confidence: 97%

High-grade intra-epithelial neoplasia and prostate cancer in Dibombari, Cameroon

Angwafo

Zaher

Befidi-Mengue

et al. 2003

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

High-grade prostatic intra-epithelial neoplasia (HGPIN) occurs a decade earlier in men of African descent in the US and Brazil, compared to white men. Prostate cancer incidence and mortality is worse in the African-American than in US white men. Sub-Saharan Africa was thought to be a low incidence area. This disparity has been attributed to lifestyle factors such as diet. We report the results of prostatic biopsies, from an ongoing national prostate cancer survey. One hundred and eleven men aged 40 y and over were recruited for medical interview (AUA symptom score), prostate specific antigen (PSA) assay and digital rectal examination (DRE). Between six and 10 cores of random digitally guided needle biopsies were performed on 24 subjects that had either suspicious prostates on digital rectal examination þ / or PSA 4 ng/ml. All lesions of the prostate were described on routine histopathology. The Gleason score and proportion of tissue involved with cancer, was determined. Eight men had benign prostatic hyperplasia (BPH), six had cancer, another six had low grade intra-epithelial neoplasia, two had HGPIN, there was one case of BPH and chronic prostatitis and one case of chronic prostatitis only. The cancer patients were aged 58 -75 y (mean 66.93 y). Gleason scores ranged from 5 to 9, there was one score of 3. Cancer made up 20 -80% tissue samples. HGPIN was found in two cases (mean age 58 y). Significant prostate cancer and the pre-cancerous lesion HGPIN exist in Dibombari, Cameroon. The purported low incidence of prostate cancer may reflect cultural and economic barriers to health care.

show abstract

Stage at presentation and survival of white and black patients with prostate carcinoma

Cited by 132 publications

References 9 publications

Sharpening the Tools for Prostate Cancer Detection in the PSA Era: What's the Point?

Sharpening the Tools for Prostate Cancer Detection in the PSA Era: What's the Point?

Use of androgen deprivation therapy for metastatic prostate cancer in older men

High-grade intra-epithelial neoplasia and prostate cancer in Dibombari, Cameroon

Contact Info

Product

Resources

About